Full cycle

CS1031 Tampa Pharma, DST Recorded Full Cycle on March 1, 2018, on a Single Sponsor Announcement

The disposition entry records no sale price and no hold period, and the announcement it cites is headed as the completion of an offering.

Published Updated

Top1031's record shows CS1031 Tampa Pharma, DST reaching full cycle on March 1, 2018, marked as a property sale. The entry for the Delaware Statutory Trust (DST) rests on one sponsor announcement, which states the Trust was taken full cycle in record time, returning over 141% of equity to investors, as reported by the sponsor in that PR Newswire release.

That release is carried on PR Newswire under the name Capital Square 1031. Its address reads capital-square-1031-completes-tampa-officerd-dst-offering-in-record-time, and the Altswire item cited alongside it repeats the same wording. The third citation on the record is page four of the sponsor's PR Newswire newsroom index rather than an individual release. A completed offering and a completed disposition are separate events, and Top1031 did not obtain the body text of the release for this report. Which of the two the announcement documents, or whether it documents both, is not settled by the material in hand. The return figure and the property-sale label trace to that one document.

Neither a price for the transaction nor a hold period is filled in on the record. The Trust's first Form D and the recorded exit date fall in the same quarter of 2018.

The offering as filed


Trust

CS1031 Tampa Pharma, DST

Sponsor

Capital Square

SEC CIK

1726241

First filing

Form D, January 2, 2018

Exemption

506(c)

Total offering amount

$3,671,000

Minimum investment

$25,000

Asset class

Commercial

Basis recorded for the exit

Sponsor announcement; confidence recorded as medium

Before this entry, Capital Square's cumulative full-cycle count at Top1031 stood at zero.

The buyer and the terms of the disposition appear nowhere in the material on the record, and that material identifies the underlying property no further than its asset class.